Mills Stephen J, Luyten Tomas, Erneux Christophe, Parys Jan B, Potter Barry V L
Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK.
Laboratory of Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine, KU Leuven, Campus Gasthuisberg O/N-1, Herestraat 49, Bus 802, 3000 Leuven, Belgium.
Messenger (Los Angel). 2012 Dec 1;1(2):167-181. doi: 10.1166/msr.2012.1016.
Inositol 1,4,5-trisphosphate [Ins(1,4,5)P] mobilizes intracellular Ca through the Ins(1,4,5)P receptor [InsPR]. Although some progress has been made in the design of synthetic InsPR partial agonists and antagonists, there are still few examples of useful small molecule competitive antagonists. A "multivalent" approach is explored and new dimeric polyphosphorylated aromatic derivatives were designed, synthesized and biologically evaluated. The established weak InsPR ligand benzene 1,2,4-trisphosphate [Bz(1,2,4)P] is dimerized through its 5-position in two different ways, first directly as the biphenyl derivative biphenyl 2,2',4,4',5,5'-hexakisphosphate, [BiPh(2,2',4,4',5,5')P] and with its regioisomeric biphenyl 3,3',4,4',5,5'-hexakisphosphate [BiPh(3,3',4,4',5,5')P]. Secondly, a linker motif is introduced in a flexible ethylene-bridged dimer () with its corresponding 1,2-bisphosphate dimer (), both loosely analogous to the very weak antagonist 1,2-bis(2-aminophenoxy)ethane-'-tetraacetic acid (BAPTA ). In permeabilized L15 fibroblasts overexpressing type 1 InsPR, BiPh(2,2',4,4',5,5')P () inhibits Ins(1,4,5)P-induced Ca release in a apparently competitive fashion [IC 187 nM] and the Bz(1,2,4)P dimer () is only slightly weaker [IC 380 nM]. Compounds were also evaluated against type I Ins(1,4,5)P 5-phosphatase. All compounds are resistant to dephosphorylation, with BiPh(2,2',4,4',5,5')P (), being the most effective inhibitor of any biphenyl derivative synthesized to date [IC 480 nM] and the Bz(1,2,4)P ethylene dimer () weaker [IC 3.55 μM]. BiPh(3,3',4,4',5,5')P () also inhibits 5-phosphatase [IC 730 nM] and exhibits unexpected Ca releasing activity [EC 800 nM]. Thus, relocation of only a single mirrored phenyl phosphate group in () from that of antagonist () does not markedly change enzyme inhibitory activity, but elicits a dramatic switch in Ca-releasing activity. Such new agents demonstrate the power of the multivalent approach and may be useful to investigate the chemical biology of signaling through InsPR and as templates for further design.
肌醇1,4,5 -三磷酸[Ins(1,4,5)P]通过肌醇1,4,5 -三磷酸受体[InsPR]动员细胞内钙离子。尽管在合成InsPR部分激动剂和拮抗剂的设计方面已取得一些进展,但有用的小分子竞争性拮抗剂的例子仍然很少。本文探索了一种“多价”方法,设计、合成并对新型二聚体多磷酸化芳香族衍生物进行了生物学评估。已确定的弱InsPR配体苯1,2,4 -三磷酸[Bz(1,2,4)P]通过其5位以两种不同方式二聚化,首先直接形成联苯衍生物联苯2,2',4,4',5,5'-六磷酸[BiPh(2,2',4,4',5,5')P]及其区域异构体联苯3,3',4,4',5,5'-六磷酸[BiPh(3,3',4,4',5,5')P]。其次,在一个柔性乙烯桥连二聚体()中引入连接基序及其相应的1,2 -二磷酸二聚体(),两者都与非常弱的拮抗剂1,2 -双(2 -氨基苯氧基)乙烷 - N,N,N',N'-四乙酸(BAPTA)有一定相似性。在过表达1型InsPR的透化L15成纤维细胞中,BiPh(2,2',4,4',5,5')P()以明显竞争性方式抑制Ins(1,4,5)P诱导的钙释放[IC50 187 nM],而Bz(1,2,4)P二聚体()仅稍弱一些[IC50 380 nM]。还针对I型肌醇1,4,5 -三磷酸5 -磷酸酶对化合物进行了评估。所有化合物都抗去磷酸化,BiPh(2,2',4,4',5,5')P()是迄今为止合成的任何联苯衍生物中最有效的抑制剂[IC50 480 nM],而Bz(1,2,4)P乙烯二聚体()较弱[IC50 3.55 μM]。BiPh(3,3',4,4',5,5')P()也抑制5 -磷酸酶[IC50 730 nM]并表现出意想不到的钙释放活性[EC50 800 nM]。因此,()中仅一个镜像苯基磷酸基团相对于拮抗剂()的位置重新定位,并没有显著改变酶抑制活性,但却引发了钙释放活性的巨大转变。这类新型试剂展示了多价方法的威力,可能有助于研究通过InsPR的信号转导化学生物学,并作为进一步设计的模板。